Dabigatran: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 24: Line 24:
'''| [[Dabigatran dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Dabigatran dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Dabigatran contraindications|Contraindications]]'''
'''| [[Dabigatran contraindications|Contraindications]]'''
'''| [[Dabigatran warnings|Warnings and Precautions]]'''
'''| [[Dabigatran Warnings and Precautions|Warnings and Precautions]]'''
'''| [[Dabigatran adverse reactions|Adverse Reactions]]'''
'''| [[Dabigatran adverse reactions|Adverse Reactions]]'''
'''| [[Dabigatran drug interactions|Drug Interactions]]'''
'''| [[Dabigatran drug interactions|Drug Interactions]]'''

Revision as of 17:36, 31 January 2014


Dabigatran
Black Box Warning
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration and Monitoring
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient information
Precautions with Alcohol
Brand Names
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information, click here

Overview

Dabigatran is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications, for some of which it may replace warfarin as the preferred anticoagulant. It is orally administered as the prodrug dabigatran etexilate (planned trade names Rendix and Pradaxa). It was developed by pharmaceutical company Boehringer-Ingelheim.

Category

Anticoagulants:Direct thrombin (II) inhibitors

US Brand Names

PRADAXA®

FDA Package Insert

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.

References

Template:WikiDoc Sources